{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-24-001681","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.369005+00:00","generated_at":"2026-06-02T03:48:53.504167+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entera Bio Q1 net loss $2.0M; cash $9.2M; FDA catalyst path for EB613","bullets":["Q1 net loss $2.0M ($0.05 per share) vs $2.2M ($0.08) in Q1 2023.","Cash $9.2M at March 31, 2024; runway into Q3 2025.","R&D expenses $0.7M (down from $0.9M); G&A flat at $1.3M.","FDA to rule on BMD as surrogate for fractures within 10 months – key catalyst for EB613 Phase 3.","Oral GLP-2 tablets showed 10-fold higher plasma exposure vs teduglutide; OXM PK data expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-24-001681","json":"https://secwatch.observer/filing/0001178913-24-001681.json","markdown":"https://secwatch.observer/filing/0001178913-24-001681.md","text":"https://secwatch.observer/filing/0001178913-24-001681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/0001178913-24-001681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/zk2431441.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:48:53.504167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5c564264086fa2700f4443ca8222c17d549ccf8","claim":"Entera Bio Ltd. reported the quarter ended March 31, 2024 results: net income $2.0 million, EPS $0.05 per ordinary share (basic and diluted).","evidence_excerpt":"Net loss was $2.0 million, or $0.05 per ordinary share (basic and diluted), for the period ended March 31, 2024, as compared to $2.2 million, or $0.08 per ordinary share (basic and diluted), for the period ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/0001178913-24-001681-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$2.0 million"},{"label":"EPS","value":"$0.05 per ordinary share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}